How Patients Became Medical Consumers

In seventeenth- and eighteenth-century England, sick people and their households drew on physicians, surgeons, apothecaries, midwives, remedy sellers, and domestic knowledge. These sources of help could be combined. A family might prepare a familiar medicine, consult a neighbour, and pay a practitioner during the same illness. Household healing was part of this world of exchange, not simply an alternative to it.

Roy Porter's study of patients in England between about 1660 and 1800 emphasises their active management of illness and dealings with practitioners. Those who could pay might compare reputations, seek another opinion, or dispute an account. Practitioners depended on recommendations and repeat custom; a professional title did not remove the need to satisfy clients.

Yet the medical marketplace did not consist of equally independent customers. A study of eighteenth-century patients and contract law shows how married women's and minors' limited contractual capacity, and employers' responsibilities for servants and apprentices, complicate that picture. The person receiving treatment was not necessarily the person choosing or paying for it. Poverty, household authority, and local availability restricted choice long before modern insurance existed.

Proprietary remedies made medicine a recognisable consumer trade. Newspapers, handbills, packaging, and testimonials promoted named products to people who might never meet their manufacturers. Historians studying commercial medicine in early modern England place this expansion within a wider growth of consumer society. Familiarity with a brand could travel farther than personal knowledge of a healer.

The label “patent medicine” did not mean that every product carried a patent, still less that its benefits had been independently established. Sellers offered accounts of recovery and promises of relief; buyers faced the problem of judging claims when ingredients, manufacturing practices, and evidence were difficult to assess. The history of medicinal substances and manufactured drugs therefore includes the history of how claims became accountable.

In the United States, the 1906 Pure Food and Drugs Act prohibited interstate commerce in adulterated and misbranded foods and drugs. It did not establish the later system of premarket proof of effectiveness. The 1938 Federal Food, Drug, and Cosmetic Act required new drugs to be shown safe before marketing, and the 1962 drug amendments added an effectiveness requirement. These were distinct stages in consumer protection: a popular product and a demonstrated treatment were increasingly subject to different standards.

During the nineteenth and twentieth centuries, formal education, licensing, laboratory investigation, and specialist institutions strengthened organised medicine. The timing and reach of these changes differed across countries. They did not eliminate lay knowledge or commercial competition, but they increased the importance of credentials and resources that patients could not readily evaluate for themselves.

The hospital's growing clinical authority made this imbalance especially visible. Records, examinations, and laboratory findings translated illness into categories used by professional teams. Patients contributed symptoms and histories, but institutions controlled much of the interpretation and routine. A paying patient could still have little influence over what was explained or who participated in an examination.

Paternalism described a relationship in which clinicians claimed authority to decide what served a patient's interests, sometimes limiting disclosure or participation. It was never the only relationship in medicine, and patients continued to negotiate, resist, and change practitioners. Nevertheless, challenging professional judgement required more than the ability to purchase a consultation.

As medical care became more institutionally complex, payment increasingly involved organisations beyond the household. Insurers, employers, and public authorities could purchase or finance services on behalf of patients. This could make care available that an individual could not otherwise afford, while placing decisions about coverage and provision elsewhere.

Britain's National Health Service, launched in 1948, established a publicly financed service intended to provide care free at the point of delivery. Subsequent charges for some services qualified that principle. Its founding nevertheless supplied a different basis for access from a direct transaction between seller and buyer: patients could claim care through membership of a public system.

In the United States, employment-based insurance and public programmes developed alongside direct payment. The creation of Medicare and Medicaid in 1965 expanded the federal role in financing care. Neither country fits a simple division between passive public patients and active private consumers. In both, the person experiencing illness could be different from the institution controlling the money, and patients could seek accountability through complaints, representation, or collective pressure as well as changing providers.

During the 1960s and 1970s, challenges to institutional authority gave new force to demands for disclosure, consent, and respectful treatment. Civil-rights campaigns, feminism, consumer protection, and debates about research ethics contributed to this climate. These movements did not share one programme, but they questioned the assumption that expertise alone entitled an institution to decide for others.

The American Hospital Association adopted its Patient's Bill of Rights in 1973. It expressed expectations about information, participation, privacy, and refusal of treatment. A professional association's statement was not itself a universal statute, and declaring rights did not ensure their enforcement. It nevertheless made the patient visible as someone to whom a hospital owed explanations and obligations.

Informed consent concerned the conditions under which a person could authorise an intervention, including understanding relevant information and having a meaningful opportunity to decide. Its development varied by jurisdiction and setting. For this history, the central distinction is that a right to participate does not depend on shopping: a person receiving publicly financed or charitable care can claim a voice just as a fee-paying patient can.

The Boston group behind Our Bodies, Ourselves began meeting in 1969. Its 1970 booklet, Women and Their Bodies, became Our Bodies, Ourselves in 1971. Combining research with discussion of women's experiences, the project challenged the scarcity of accessible information about bodies, sexuality, and health care. Knowledge was something women could investigate and share, rather than receive only during a consultation.

This was collective education, not simply advice on selecting a doctor. It questioned whose experiences counted and how gender shaped the clinical encounter. The book's later translations and adaptations also show that patient participation travelled through organisations and local reinterpretation, not through a single universal model.

AIDS activism in the 1980s and 1990s extended this challenge into research. Activists learned the language of trials and drug regulation, disputed barriers to participation, and demanded access to investigational treatments. A 1990 conference account of access to AIDS therapies records disagreements about trial locations and access outside controlled studies. The National Library of Medicine's history of AIDS activism also documents pressure on federal research institutions.

Urgency did not dissolve the difficulty of determining whether a treatment worked. The dispute concerned how to combine credible evidence with the needs of people facing life-threatening illness. Read alongside the history of evidence-based medicine, it shows patients entering arguments about how knowledge should be produced, as well as how care should be delivered.

By the late twentieth century, the informed patient was also an important audience for commercial promotion. In the United States, prescription-drug advertising addressed people who could request a product but still needed a prescriber to obtain it. The FDA's 1997 draft guidance, finalised in 1999, clarified how broadcast advertisements could provide access to fuller product information. It did not mark the invention of drug advertising or remove prescription requirements.

Such advertising connected an invitation to ask questions with a manufacturer's interest in selling a particular medicine. The wider circulation of information could bring a condition or treatment into discussion, while the selection and presentation of that information remained commercially motivated. The language of patient initiative could serve both participation and promotion.

The web later widened access to medical publications, patient accounts, support groups, and marketing. It made some information easier to obtain without a professional intermediary, but did not erase the task of assessing its quality. Access to a page was not equivalent to access to treatment, and a larger volume of information did not by itself settle competing claims.

Calling patients consumers drew attention to information, responsiveness, and accountability. It also risked treating medical care as a purchase made by someone with time, money, alternatives, and the ability to judge quality. Severe illness, an emergency, distance from services, or dependence on a payer could make that picture unrealistic. Historical changes in the language of choice must therefore be distinguished from changes in people's practical options.

The history traced here is principally British and American. It cannot stand for every society, and even within these countries rights statements and activist publications reveal aspirations more readily than everyday implementation. Household records, institutional policies, advertising, and campaign archives illuminate different kinds of patient power.

Patients became medical consumers through overlapping developments, not a single emancipation from passivity. Markets made them customers; public provision and insurance changed who paid; rights movements demanded explanation and consent; activists claimed a role in knowledge-making. The enduring question is which decisions patients could actually influence, individually or together, and what made that influence possible.